XKRX323990
Market cap114mUSD
Jan 09, Last price
10,950.00KRW
1D
-0.09%
1Q
-21.28%
IPO
3.06%
Name
Vaxcell Bio Therapeutics
Chart & Performance
P/E
—
P/S
12,146.61
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
14m
Net income
-10.27b
L+50.53%
CFO
-9.42b
L+55.89%
Earnings
Mar 17, 2025
Profile
Vaxcell-Bio Therapeutics Co., Ltd. develops and sells cancer immune cell therapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 13,723 | ||||
Cost of revenue | 8,129,887 | 4,438,482 | |||
Unusual Expense (Income) | |||||
NOPBT | (8,116,164) | (4,438,482) | |||
NOPBT Margin | |||||
Operating Taxes | 1,427,278 | ||||
Tax Rate | |||||
NOPAT | (8,116,164) | (5,865,760) | |||
Net income | (10,274,079) 50.53% | (6,825,051) 43.30% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 71,257,044 | ||||
BB yield | -16.19% | ||||
| Debt | |||||
Debt current | 216,895 | 46,515 | |||
Long-term debt | 505,565 | 163,961 | |||
Deferred revenue | |||||
Other long-term liabilities | 418,451 | 470,013 | |||
Net debt | (39,152,759) | (610,339) | |||
| Cash flow | |||||
Cash from operating activities | (9,422,992) | (6,044,626) | |||
CAPEX | (198,500) | (290,207) | |||
Cash from investing activities | (51,786,686) | 4,333,343 | |||
Cash from financing activities | 69,866,253 | (207,849) | |||
FCF | (8,722,784) | (5,602,470) | |||
| Balance | |||||
Cash | 50,046,236 | 20,392,123 | |||
Long term investments | (10,171,017) | (19,571,308) | |||
Excess cash | 39,874,533 | 820,814 | |||
Stockholders' equity | (32,040,501) | (25,561,176) | |||
Invested Capital | 116,313,450 | 49,463,694 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 19,607 | 20,219 | |||
Price | 22,450.00 -21.11% | 28,458.33 -21.31% | |||
Market cap | 440,177,621 -23.50% | 575,385,395 -20.72% | |||
EV | 401,024,863 | 574,775,056 | |||
EBITDA | (7,716,481) | (4,127,139) | |||
EV/EBITDA | |||||
Interest | 43,665 | 16,679 | |||
Interest/NOPBT | |||||